Revance Therapeutics, Inc. (RVNC)

3.6725 -0.0175 (-0.47%) 市場開市。 截至 11:29AM EDT。

Revance Therapeutics, Inc.

1222 Demonbreun Street
Suite 2000
Nashville, TN 37203
United States
615 724 7755
https://www.revance.com

版塊: Healthcare
行業: Biotechnology
全職員工: 597

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Mark J. Foley	CEO & Director	1.26M	無	1965
Mr. Tobin C. Schilke	CFO & Principal Accounting Officer	731.58k	無	1975
Mr. Dwight O. Moxie	Chief Legal Officer & General Counsel	713.82k	無	1976
Jessica Serra	Head of Investor Relations & ESG	無	無	無
Ms. Jeanie D. Herbert	Senior Director of Investor Relations & Corporate Communications	無	無	無
Ms. Taryn Conway	Vice President of Marketing	無	無	無
Ms. Amie Krause	Chief People Officer	無	無	無
Dr. Conor Gallagher	Head of Medical Affairs & Aesthetics	無	無	無
Dr. David A. Hollander M.B.A., M.D.	Chief Medical Officer of Global Therapeutics Franchise Lead	無	無	1975
Ms. Erica Jordan	Chief Commercial Officer	無	無	1977

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

公司管治

截至 2024年4月29日 止，Revance Therapeutics, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：6；董事會：5；股東權利：7；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。